Skip to main content

Advertisement

SpringerLink
Log in

Ocular Involvement in Systemic Autoimmune Diseases

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Eye involvement represents a common finding in patients with systemic autoimmune diseases, particularly rheumatoid arthritis, Sjogren syndrome, seronegative spondyloarthropathy, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The eye is a privileged immune site but commensal bacteria are found on the ocular surface. The eye injury may be inflammatory, vascular or infectious, as well as iatrogenic, as in the case of hydroxychloroquine, chloroquine, corticosteroids, and bisphosphonates. Manifestations may affect different components of the eye, with episcleritis involving the episclera, a thin layer of tissue covering the sclera; scleritis being an inflammation of the sclera potentially leading to blindness; keratitis, referring to corneal inflammation frequently associated with scleritis; and uveitis as the inflammation of the uvea, including the iris, ciliary body, and choroid, subdivided into anterior, posterior, or panuveitis. As blindness may result from the eye involvement, clinicians should be aware of the possible manifestations and their management also independent of the ophthalmologist opinion as the therapeutic approach generally points to the underlying diseases. In some cases, the eye involvement may have a diagnostic implication, as for episcleritis in rheumatoid arthritis, or acute anterior uveitis in seronegative spondyloarthritis. Nonetheless, some conditions lack specificity, as in the case of dry eye which affects nearly 30 % of the general population. The aim of this review is to elucidate to non-ophthalmologists the major ocular complications of rheumatic diseases and their specific management and treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gaubitz M (2006) Epidemiology of connective tissue disorders. Rheumatology (Oxford) 45 Suppl 3:iii3-4. doi:10.1093/rheumatology/kel282

  2. Selmi C, Brunetta E, Raimondo MG, Meroni PL (2012) The X chromosome and the sex ratio of autoimmunity. Autoimmun Rev 11(6–7):A531–537. doi:10.1016/j.autrev.2011.11.024

    Article  CAS  PubMed  Google Scholar 

  3. Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9(5):A247–250. doi:10.1016/j.autrev.2010.02.004

    Article  PubMed  Google Scholar 

  4. McCluskey P, Powell RJ (2004) The eye in systemic inflammatory diseases. Lancet 364(9451):2125–2133. doi:10.1016/S0140-6736(04)17554-5

    Article  PubMed  Google Scholar 

  5. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E (2014) Diagnosis and classification of rheumatoid arthritis. J Autoimmun 48–49:26–30. doi:10.1016/j.jaut.2014.01.027

    Article  PubMed  Google Scholar 

  6. Bascherini V, Granato C, Lopalco G, Emmi G, Vannozzi L, Bacherini D, Franceschini R, Iannone F, Salerni A, Molinaro F, Messina M, Frediani B, Selmi C, Rigante D, Cantarini L (2015) The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clin Rheumatol 34(7):1171–1180. doi:10.1007/s10067-015-2920-3

    Article  PubMed  Google Scholar 

  7. Kobak S, Deveci H (2010) Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis 13(3):e11–15. doi:10.1111/j.1756-185X.2010.01478.x

    Article  PubMed  Google Scholar 

  8. Akpek EK, Gottsch JD (2003) Immune defense at the ocular surface. Eye (Lond) 17(8):949–956. doi:10.1038/sj.eye.6700617

    Article  CAS  Google Scholar 

  9. Zhou R, Caspi RR (2010) Ocular immune privilege. F1000 Biol Rep 2. doi:10.3410/B2-3

  10. Perez VL, Saeed AM, Tan Y, Urbieta M, Cruz-Guilloty F (2013) The eye: a window to the soul of the immune system. J Autoimmun 45:7–14. doi:10.1016/j.jaut.2013.06.011

    Article  CAS  PubMed  Google Scholar 

  11. Tong L, Thumboo J, Tan YK, Wong TY, Albani S (2014) The eye: a window of opportunity in rheumatoid arthritis? Nat Rev Rheumatol 10(9):552–560. doi:10.1038/nrrheum.2014.85

    Article  CAS  PubMed  Google Scholar 

  12. Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P (2013) Scleritis: challenges in immunopathogenesis and treatment. Discov Med 16(88):153–157

    PubMed  Google Scholar 

  13. Kuhn A, Landmann A (2014) The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 48–49:14–19. doi:10.1016/j.jaut.2014.01.021

    Article  PubMed  Google Scholar 

  14. Aoki H, Hiraoka M, Hashimoto M, Ohguro H (2015) Systemic cyclosporine therapy for scleritis: a proposal of a novel system to assess the activity of scleritis. Case Rep Ophthalmol 6(2):149–157. doi:10.1159/000430490

    Article  PubMed Central  PubMed  Google Scholar 

  15. Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, de Saint SA, Butler NJ, Smith JR, Rosenbaum JT (2014) Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol 132(5):572–578. doi:10.1001/jamaophthalmol.2013.8179

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Sauer A, Meyer N, Bourcier T, French Study Group for Contact Lens-Related Microbial K (2015) Risk factors for contact lens-related microbial keratitis: a case–control multicenter study. Eye Contact Lens. doi:10.1097/ICL.0000000000000180

    PubMed  Google Scholar 

  17. Yagci A (2012) Update on peripheral ulcerative keratitis. Clin Ophthalmol 6:747–754. doi:10.2147/OPTH.S24947

    Article  PubMed Central  PubMed  Google Scholar 

  18. Generali E, Ceribelli A, Massarotti M, Cantarini L, Selmi C (2015) Seronegative reactive spondyloarthritis and the skin. Clin Dermatol 33(5):531–537. doi:10.1016/j.clindermatol.2015.05.004

    Article  PubMed  Google Scholar 

  19. Rotondo C, Lopalco G, Iannone F, Vitale A, Talarico R, Galeazzi M, Lapadula G, Cantarini L (2015) Mucocutaneous involvement in Behcet’s disease: how systemic treatment has changed in the last decades and future perspectives. Mediators Inflamm 2015:451675. doi:10.1155/2015/451675

    Article  PubMed Central  PubMed  Google Scholar 

  20. Foeldvari I (2014) Ocular involvement in juvenile idiopathic arthritis: classification and treatment. Clin Rev Allergy Immunol. doi:10.1007/s12016-014-8436-9

    PubMed  Google Scholar 

  21. Selmi C (2014) Diagnosis and classification of autoimmune uveitis. Autoimmun Rev 13(4–5):591–594. doi:10.1016/j.autrev.2014.01.006

    Article  CAS  PubMed  Google Scholar 

  22. Prabhu SS, Shtein RM, Michelotti MM, Cooney TM (2015) Topical cyclosporine A 0.05% for recurrent anterior uveitis. Br J Ophthalmol. doi:10.1136/bjophthalmol-2015-307251

    PubMed  Google Scholar 

  23. Cordero-Coma M, Sobrin L (2015) Anti-tumor necrosis factor-alpha therapy in uveitis. Surv Ophthalmol. doi:10.1016/j.survophthal.2015.06.004

    PubMed  Google Scholar 

  24. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785–796. doi:10.1016/j.ophtha.2013.09.048, e783

    Article  PubMed  Google Scholar 

  25. Calvo-Rio V, de la Hera D, Beltran-Catalan E, Blanco R, Hernandez M, Martinez-Costa L, Loricera J, Canal J, Ventosa J, Ortiz-Sanjuan F, Pina T, Gonzalez-Vela MC, Rodriguez-Cundin P, Gonzalez-Gay MA (2014) Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32(4 Suppl 84):S54–57

    PubMed  Google Scholar 

  26. Schwartzman S, Schwartzman M (2014) The use of biologic therapies in uveitis. Clin Rev Allergy Immunol. doi:10.1007/s12016-014-8455-6

    PubMed  Google Scholar 

  27. Androudi S, Dastiridou A, Symeonidis C, Kump L, Praidou A, Brazitikos P, Kurup SK (2013) Retinal vasculitis in rheumatic diseases: an unseen burden. Clin Rheumatol 32(1):7–13. doi:10.1007/s10067-012-2078-1

    Article  PubMed  Google Scholar 

  28. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11. doi:10.1002/art.37715

    Article  CAS  PubMed  Google Scholar 

  29. Chimenti MS, Ballanti E, Triggianese P, Perricone R (2014) Vasculitides and the complement system: a comprehensive review. Clin Rev Allergy Immunol. doi:10.1007/s12016-014-8453-8

    PubMed  Google Scholar 

  30. Grossman C, Barshack I, Bornstein G, Ben-Zvi I (2015) Is temporal artery biopsy essential in all cases of suspected giant cell arteritis? Clin Exp Rheumatol 33(2 Suppl 89):S-84–89

    Google Scholar 

  31. Nesher G (2014) The diagnosis and classification of giant cell arteritis. J Autoimmun 48–49:73–75. doi:10.1016/j.jaut.2014.01.017

    Article  PubMed  Google Scholar 

  32. Aschwanden M, Imfeld S, Staub D, Baldi T, Walker UA, Berger CT, Hess C, Daikeler T (2015) The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol 33(2 Suppl 89):S-113–115

    Google Scholar 

  33. Khan A, Dasgupta B (2015) Imaging in giant cell arteritis. Curr Rheumatol Rep 17(8):527. doi:10.1007/s11926-015-0527-y

    Article  Google Scholar 

  34. Biousse V, Newman NJ (2015) Ischemic optic neuropathies. N Engl J Med 372(25):2428–2436. doi:10.1056/NEJMra1413352

    Article  CAS  PubMed  Google Scholar 

  35. Ponte C, Rodrigues AF, O’Neill L, Luqmani RA (2015) Giant cell arteritis: current treatment and management. World J Clin Cases 3(6):484–494. doi:10.12998/wjcc.v3.i6.484

    PubMed Central  PubMed  Google Scholar 

  36. Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P, Mouthon L, Guillevin L, French Vasculitis Study G (2014) Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients. J Autoimmun 50:135–141. doi:10.1016/j.jaut.2014.03.002

    Article  CAS  PubMed  Google Scholar 

  37. Gu J, Zhou S, Ding R, Aizezi W, Jiang A, Chen J (2013) Necrotizing scleritis and peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Ophthalmol Ther 2(2):99–111. doi:10.1007/s40123-013-0016-1

    Article  PubMed Central  PubMed  Google Scholar 

  38. Mouthon L, Dunogue B, Guillevin L (2014) Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun 48–49:99–103. doi:10.1016/j.jaut.2014.01.018

    Article  PubMed  Google Scholar 

  39. Kubal AA, Perez VL (2010) Ocular manifestations of ANCA-associated vasculitis. Rheum Dis Clin North Am 36(3):573–586. doi:10.1016/j.rdc.2010.05.005

    Article  PubMed  Google Scholar 

  40. Takeuchi M, Kastner DL, Remmers EF (2015) The immunogenetics of Behcet’s disease: a comprehensive review. J Autoimmun. doi:10.1016/j.jaut.2015.08.013

    PubMed  Google Scholar 

  41. Criteria for diagnosis of Behcet’s disease (1990) International study group for Behcet’s Disease. Lancet 335(8697):1078–1080

    Google Scholar 

  42. Yazici H, Yazici Y (2014) Criteria for Behcet’s disease with reflections on all disease criteria. J Autoimmun 48–49:104–107. doi:10.1016/j.jaut.2014.01.014

    Article  PubMed  Google Scholar 

  43. Ozyazgan Y, Ucar D, Hatemi G, Yazici Y (2014) Ocular involvement of Behcet’s syndrome: a comprehensive review. Clin Rev Allergy Immunol. doi:10.1007/s12016-014-8425-z

    PubMed  Google Scholar 

  44. Park UC, Kim TW, Yu HG (2014) Immunopathogenesis of ocular Behcet’s disease. J Immunol Res 2014:653539. doi:10.1155/2014/653539

    Article  PubMed Central  PubMed  Google Scholar 

  45. Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martin L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L (2014) Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediators Inflamm 2014:107421. doi:10.1155/2014/107421

    Article  PubMed Central  PubMed  Google Scholar 

  46. Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Behcet N (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74. doi:10.1016/j.jaut.2015.06.005

    Article  CAS  PubMed  Google Scholar 

  47. Nava F, Ghilotti F, Maggi L, Hatemi G, Del Bianco A, Merlo C, Filippini G, Tramacere I (2014) Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behcet’s Syndrome. Cochrane Database Syst Rev 12:CD010729. doi:10.1002/14651858.CD010729.pub2

    PubMed  Google Scholar 

  48. Sharma A, Hindman HB (2014) Aging: a predisposition to dry eyes. J Ophthalmol 2014:781683. doi:10.1155/2014/781683

    Article  PubMed Central  PubMed  Google Scholar 

  49. Cornec D, Saraux A, Jousse-Joulin S, Pers JO, Boisrame-Gastrin S, Renaudineau Y, Gauvin Y, Roguedas-Contios AM, Genestet S, Chastaing M, Cochener B, Devauchelle-Pensec V (2014) The differential diagnosis of dry eyes, dry mouth, and parotidomegaly: a comprehensive review. Clin Rev Allergy Immunol. doi:10.1007/s12016-014-8431-1

    PubMed  Google Scholar 

  50. Yagci A, Gurdal C (2014) The role and treatment of inflammation in dry eye disease. Int Ophthalmol 34(6):1291–1301. doi:10.1007/s10792-014-9969-x

    Article  PubMed  Google Scholar 

  51. Hessen M, Akpek EK (2014) Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res 9(2):240–250

    PubMed Central  PubMed  Google Scholar 

  52. Colafrancesco S, Perricone C, Priori R, Valesini G, Shoenfeld Y (2014) Sjogren’s syndrome: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun 51:10–16. doi:10.1016/j.jaut.2014.03.003

    Article  CAS  PubMed  Google Scholar 

  53. Cornec D, Jamin C, Pers JO (2014) Sjogren’s syndrome: where do we stand, and where shall we go? J Autoimmun 51:109–114. doi:10.1016/j.jaut.2014.02.006

    Article  PubMed  Google Scholar 

  54. Goules AV, Tzioufas AG, Moutsopoulos HM (2014) Classification criteria of Sjogren’s syndrome. J Autoimmun 48–49:42–45. doi:10.1016/j.jaut.2014.01.013

    Article  PubMed  Google Scholar 

  55. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, Nelson JD, Nichols KK, Pflugfelder SC, Tanzer JM, Asbell P, Hammitt K, Jacobs DS (2015) Clinical guidelines for management of dry eye associated with Sjogren disease. Ocul Surf 13(2):118–132. doi:10.1016/j.jtos.2014.12.001

    Article  PubMed  Google Scholar 

  56. Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dorner T, Ravaud P, Mariette X, Vitali C (2014) Outcome measures for primary Sjogren’s syndrome: a comprehensive review. J Autoimmun 51:51–56. doi:10.1016/j.jaut.2013.12.010

    Article  PubMed  Google Scholar 

  57. Valim V, Trevisani VF, de Sousa JM, Vilela VS, Belfort R Jr (2014) Current approach to dry eye disease. Clin Rev Allergy Immunol. doi:10.1007/s12016-014-8438-7

    PubMed  Google Scholar 

  58. Schultz C (2014) Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 6:37–42. doi:10.4137/OED.S16067

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Wan KH, Chen LJ, Young AL (2015) Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf 13(3):213–225. doi:10.1016/j.jtos.2014.12.006

    Article  PubMed  Google Scholar 

  60. Liu A, Ji J (2014) Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit 20:1583–1589. doi:10.12659/MSM.891364

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Alio JL, Rodriguez AE, WrobelDudzinska D (2015) Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr Opin Ophthalmol 26(4):325–332. doi:10.1097/ICU.0000000000000169

    Article  PubMed  Google Scholar 

  62. Bavinger JC, DeLoss K, Mian SI (2015) Scleral lens use in dry eye syndrome. Curr Opin Ophthalmol 26(4):319–324. doi:10.1097/ICU.0000000000000171

    Article  PubMed  Google Scholar 

  63. Stelton CR, Connors DB, Walia SS, Walia HS (2013) Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol 32(6):895–898. doi:10.1007/s10067-013-2226-2

    Article  PubMed  Google Scholar 

  64. Costedoat-Chalumeau N, Dunogue B, Leroux G, Morel N, Jallouli M, Le Guern V, Piette JC, Brezin AP, Melles RB, Marmor MF (2015) A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. doi:10.1007/s12016-015-8469-8

    PubMed  Google Scholar 

  65. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of O (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118(2):415–422. doi:10.1016/j.ophtha.2010.11.017

    Article  PubMed  Google Scholar 

  66. Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 122(6):1239–1251. doi:10.1016/j.ophtha.2015.02.011, e1234

    Article  PubMed  Google Scholar 

  67. Harris E, Tiganescu A, Tubeuf S, Mackie SL (2015) The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. Curr Rheumatol Rep 17(6):513. doi:10.1007/s11926-015-0513-4

    Article  PubMed  Google Scholar 

  68. Razeghinejad MR, Katz LJ (2012) Steroid-induced iatrogenic glaucoma. Ophthalmic Res 47(2):66–80. doi:10.1159/000328630

    Article  CAS  PubMed  Google Scholar 

  69. Gurbaxani A, Fraser CL, Skalicky SE, McCluskey P (2013) Ocular complications associated with systemic medications used in allergy/immunology practice. Curr Allergy Asthma Rep 13(3):329–335. doi:10.1007/s11882-012-0333-9

    Article  CAS  PubMed  Google Scholar 

  70. Hemmati I, Wade J, Kelsall J (2012) Risedronate-associated scleritis: a case report and review of the literature. Clin Rheumatol 31(9):1403–1405. doi:10.1007/s10067-012-2035-z

    Article  PubMed  Google Scholar 

  71. Benderson D, Karakunnel J, Kathuria S, Badros A (2006) Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma 7(2):145–147. doi:10.3816/CLM.2006.n.053

    Article  PubMed  Google Scholar 

  72. Clark EM, Durup D (2015) Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks? Ther Adv Musculoskelet Dis 7(1):11–16. doi:10.1177/1759720X14566424

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Lefebvre DR, Mandeville JT, Yonekawa Y, Arroyo JG, Torun N, Freitag SK (2015) A case series and review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm:1–6. doi:10.3109/09273948.2014.942747

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Milan, Italy

    Elena Generali & Carlo Selmi

  2. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, University of Siena, Siena, Italy

    Luca Cantarini

  3. BIOMETRA Department, University of Milan, Milan, Italy

    Carlo Selmi

Authors
  1. Elena Generali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlo Selmi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Selmi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Generali, E., Cantarini, L. & Selmi, C. Ocular Involvement in Systemic Autoimmune Diseases. Clinic Rev Allerg Immunol 49, 263–270 (2015). https://doi.org/10.1007/s12016-015-8518-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-015-8518-3

Keywords

Search

Navigation